Publications by authors named "A G Eremeev"
Article Synopsis
- Expansion of CAG repeats in certain genes is linked to neurodegenerative diseases, but the mechanisms are not well understood; this study investigates how these repeats interact with RNA editing enzymes like ADAR.
- Researchers used induced pluripotent stem cells (iPSCs) and brain organoids from Huntington's disease and ataxia type 17 patients to analyze RNA editing via next-generation sequencing.
- Results showed that while some brain organoids with specific CAG repeats had decreased RNA editing, most cultures did not support the hypothesis that CAG repeats affect editing levels significantly.
This article presents the results of a comprehensive toxicity assessment of brazzein and monellin, yeast-produced recombinant sweet-tasting proteins. Excessive sugar consumption is one of the leading dietary and nutritional problems in the world, resulting in health complications such as obesity, high blood pressure, and cardiovascular disease. Although artificial small-molecule sweeteners widely replace sugar in food, their safety and long-term health effects remain debatable.
View Article and Find Full Text PDFInflammatory joint diseases, among which osteoarthritis and rheumatoid arthritis are the most common, are characterized by progressive degeneration of the cartilage tissue, resulting in the threat of limited or lost joint functionality in the absence of treatment. Currently, treating these diseases is difficult, and a number of existing treatment and prevention measures are not entirely effective and are complicated by the patients' conditions, the multifactorial nature of the pathology, and an incomplete understanding of the etiology. Cellular technologies based on induced pluripotent stem cells (iPSCs) can provide a vast cellular resource for the production of artificial cartilage tissue for replacement therapy and allow the possibility of a personalized approach.
View Article and Find Full Text PDFBackground: Dozens of transplants generated from pluripotent stem cells are currently in clinical trials. The creation of patient-specific iPSCs makes personalized therapy possible due to their main advantage of immunotolerance. However, some reports have claimed recently that aberrant gene expression followed by proteome alterations and neoantigen formation can result in iPSCs recognition by autologous T-cells.
View Article and Find Full Text PDF